Jan 08, 2020 - The EMA endorses Incyte's (INCY) MAA for pemigatinib to treat locally advanced/metastatic cholangiocarcinoma with a FGFR2 fusion that is relapsed or refractory post minimum one line of systemic therapy.
Jan 08, 2020 - A low-key week for the biotech sector, with a few pipeline and regulatory updates.
Jan 06, 2020 - Companies In The News Are: CANF, LW, INCY, NOVN
Jan 03, 2020 - BMO Capital Markets issues rating change for INCY
Jan 03, 2020 - Novan (NASDAQ:NOVN) -73% on failed SB206 study.DPW Holdings (NYSEMKT:DPW) -30% on doubts over FINRA approval of proposed acquisitions.Landec (NASDAQ:LNDC) -15% on Q2 earnings.Mereo BioPharma Group (NA
Dec 28, 2019 - Few biotech companies ever reach that valuation, and if they do, you should snap them up for your portfolio.
Dec 24, 2019 - Is (INCY) Outperforming Other Medical Stocks This Year?
Dec 16, 2019 - Does Incyte (INCY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Nov 28, 2019 - The FDA accepts and grants priority review to Incyte's (INCY) new drug application for pemigatinib as a second-line treatment for patients with FGFR2 translocated cholangiocarcinoma.
Nov 27, 2019 - Merck (MRK) receives the third approval of Keytruda for first-line non-small cell lung cancer patient population in China.